REDX Stock Overview Engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Redx Pharma Plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Redx Pharma Historical stock prices Current Share Price UK£0.15 52 Week High UK£0.38 52 Week Low UK£0.04 Beta -0.53 1 Month Change -18.92% 3 Month Change -25.00% 1 Year Change -53.85% 3 Year Change -76.92% 5 Year Change 185.71% Change since IPO -82.46%
Recent News & Updates
Redx Pharma Plc Reports Encouraging Zamaporvint (RXC004) Phase 2 Combination Data in MSS mCRC at ESMO GI Congress Jun 29
Redx to Present Zamaporvint Phase2 Data At Esmo Gi Jun 21
Redx to Present Preclinical Data on RXC008 in an Oral Presentation at ECM Congress Jun 18 Redx Pharma Provides Update on AIM Delisting Apr 30
New major risk - Share price stability Apr 03
Consensus EPS estimates upgraded to UK£0.062 loss Feb 29 See more updates
Redx Pharma Plc Reports Encouraging Zamaporvint (RXC004) Phase 2 Combination Data in MSS mCRC at ESMO GI Congress Jun 29
Redx to Present Zamaporvint Phase2 Data At Esmo Gi Jun 21
Redx to Present Preclinical Data on RXC008 in an Oral Presentation at ECM Congress Jun 18 Redx Pharma Provides Update on AIM Delisting Apr 30
New major risk - Share price stability Apr 03
Consensus EPS estimates upgraded to UK£0.062 loss Feb 29
Redx Announces That First Participant Dosed in Phase 1 Trial of RXC008 Feb 28
Full year 2023 earnings: EPS and revenues exceed analyst expectations Feb 19
Redx Pharma Plc, Annual General Meeting, Mar 14, 2024 Feb 17
New minor risk - Share price stability Feb 08
New minor risk - Market cap size Jan 30
Full year 2023 earnings: EPS and revenues exceed analyst expectations Dec 16
Redx Pharma Plc to Report Fiscal Year 2023 Results on Dec 15, 2023 Dec 12
New minor risk - Financial data availability Dec 03
New minor risk - Shareholder dilution Nov 10
Redx Pharma plc to Present Preclinical Data on RXC009, A Selective Discoidin Domain Receptor 1 Inhibitor Oct 30 Redx Pharma Plc has completed a Follow-on Equity Offering in the amount of £14.059359 million. Oct 18
Redx Pharma plc Appoints Joseph Anderson as Non-Executive Director Sep 07
Redx Pharma Plc Announces Executive Changes Aug 22
Does Redx Pharma (LON:REDX) Have A Healthy Balance Sheet? Aug 22 Redx Pharma plc Zelasudil Receives FDA Orphan Drug Designation Aug 21
New minor risk - Market cap size Aug 03
Redx Pharma Plc Announces Directorate Changes Jul 04
Is Redx Pharma (LON:REDX) Using Too Much Debt? May 22
Price target decreased by 9.9% to UK£1.32 May 19
First half 2023 earnings released: UK£0.062 loss per share (vs UK£0.035 loss in 1H 2022) May 18
Redx Pharma Plc's Discovery of Pirtobrutinib Recognised with Unveiling of Commemorative Plaque At Alderley Park May 13
Redx Pharma Plc Presents Preclinical Efficacy Data for RXC007 Showing Significant Results in Cancer-Associated Fibrosis Models May 11
Redx Pharma Plc to Report First Half, 2023 Results on May 17, 2023 May 10
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Feb 19
Redx Pharma Plc, Annual General Meeting, Mar 14, 2023 Feb 16
Redx Pharma Plc Provides Progress Updates on RXC007 Clinical Programme Feb 10
Consensus revenue estimates increase by 15%, EPS downgraded Jan 31
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Dec 21
Redx Pharma Plc to Report Q4, 2022 Results on Dec 20, 2022 Dec 13
High number of new directors Nov 16
Redx Pharma plc to Present on Potential of RXC007 in Fibrotic Diseases at Antifibrotic Drug Discovery Meeting Nov 07
Redx Pharma plc Announces First Patient Dosed in Phase 2a Trial for RXC007 Oct 11
Bullish: Analysts Just Made A Significant Upgrade To Their Redx Pharma Plc (LON:REDX) Forecasts Jul 09
Consensus revenue estimates increase by 24% Jul 08
Consensus revenue estimates increase by 31% Jun 30
Redx Pharma Announces Two Presentations Were Delivered at the Inaugural Extracellular Matrix Pharmacology Congress in Copenhagen, 23-25 June Jun 28
First half 2022 earnings released Jun 23
Redx Pharma Plc to Report Q2, 2022 Results on Jun 23, 2022 Jun 16
Redx Pharma Plc has completed a Follow-on Equity Offering in the amount of £34.261864 million. May 20
Price target increased to UK£1.70 Apr 27
High number of new directors Apr 27
Redx Pharma Plc Presents Encouraging RXC004 Preclinical Data Apr 10
Redx Pharma plc Announces Nomination of Clinical Development Candidate Mar 30
Redx Pharma Plc Announces Committee Changes Mar 10
Redx Pharma Plc, Annual General Meeting, Mar 08, 2022 Feb 12
High number of new directors Feb 02
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Jan 28
First half 2021 earnings released: UK£0.053 loss per share (vs UK£0.027 loss in 1H 2020) Jun 10
Non-Executive Chairman Iain Ross has left the company Jun 09
Redx Pharma Announces First Subject Dosed in Phase 1 Study with Lead Fibrosis Candidate RXC007, a ROCK2 Selective Inhibitor Jun 03
Redx Pharma Announce Mead Will Step Down from the Board Mar 04
Redx Pharma plc Announces Search for A US Based Chief Financial Officer Has Been Initiated Mar 03
Chief Medical Officer has left the company Mar 03
New 90-day high: UK£0.68 Feb 13
Redx Pharma Plc, Annual General Meeting, Mar 02, 2021 Feb 06
Earnings beat expectations, revenue disappoints Jan 28
Redx Pharma Plc to Report Fiscal Year 2020 Results on Jan 27, 2021 Jan 14
New 90-day low: UK£0.54 Dec 12
Redx Pharma plc Announces the Appointment of Jane Robertson as Chief Medical Officer, Effective 1 March 2021 Oct 27
New 90-day high: UK£0.68 Oct 05
New 90-day high - UK£0.60 Aug 04
Redmile Group, LLC completed the acquisition of remaining 54.5% stake in Redx Pharma Plc (AIM:REDX). Jul 30
Redx Pharma Plc announced that it expects to receive £23.63877 million in funding from Sofinnova Partners SAS, Redmile Group, LLC Jul 01 Shareholder Returns REDX GB Pharmaceuticals GB Market 7D 62.2% 0.3% 3.5% 1Y -53.8% -2.0% 10.5%
See full shareholder returns
Return vs Market: REDX underperformed the UK Market which returned 2.3% over the past year.
Price Volatility Is REDX's price volatile compared to industry and market? REDX volatility REDX Average Weekly Movement 33.2% Pharmaceuticals Industry Average Movement 6.7% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.9% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: REDX's share price has been volatile over the past 3 months.
Volatility Over Time: REDX's weekly volatility has increased from 17% to 33% over the past year.
About the Company Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn’s disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.
Show more Redx Pharma Plc Fundamentals Summary How do Redx Pharma's earnings and revenue compare to its market cap? REDX fundamental statistics Market cap UK£58.35m Earnings (TTM ) -UK£33.16m Revenue (TTM ) UK£4.20m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) REDX income statement (TTM ) Revenue UK£4.20m Cost of Revenue UK£0 Gross Profit UK£4.20m Other Expenses UK£37.36m Earnings -UK£33.16m
Last Reported Earnings
Sep 30, 2023
Earnings per share (EPS) -0.085 Gross Margin 100.00% Net Profit Margin -789.05% Debt/Equity Ratio 468.9%
How did REDX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/05/01 14:54 End of Day Share Price 2024/05/01 00:00 Earnings 2023/09/30 Annual Earnings 2023/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Redx Pharma Plc is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian White Cantor Fitzgerald Europe Martin Hall Hardman & Co. Michael Mitchell Panmure Liberum Historic (Panmure Gordon)
Show 2 more analysts 
